| pegylated liposomal doxorubicin / Generic mfg. |
NCT00653952: CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 220 | US | CAELYX, Paclitaxel HCl | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Sequus Pharmaceuticals, ALZA | Ovarian Neoplasms | | 04/00 | | |
NCT00043082: S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer |
|
|
| Completed | 3 | 61 | US | carboplatin, pegylated liposomal doxorubicin hydrochloride | Southwest Oncology Group, National Cancer Institute (NCI) | Ovarian Cancer, Peritoneal Cavity Cancer | 06/07 | 07/11 | | |
NCT00245050: Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer |
|
|
| Completed | 3 | 34 | US | pyridoxine hydrochloride, Placebo, doxorubicin HCL liposome | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer | 04/08 | 09/11 | | |
NCT00091442: A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer |
|
|
| Completed | 3 | 751 | US, Europe, RoW | Docetaxel, DOXIL, DOXIL in combination with Docataxel | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Breast Cancer | 12/08 | 12/08 | | |
NCT00011986: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
|
|
| Completed | 3 | 4312 | US | Paclitaxel, Anzatax, TAX, Carboplatin, Gemcitabine Hydrochloride, dFdC, dFdCyd, Pegylated Liposomal Doxorubicin Hydrochloride, doxorubicin HCl liposome, TLC D-99, Topotecan Hydrochloride, Hycamtin, SKF S-104864-A, TOPO, Therapeutic Conventional Surgery | Gynecologic Oncology Group, Southwest Oncology Group, Medical Research Council, National Cancer Institute (NCI) | Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer | 03/10 | 01/13 | | |
NCT01840943: A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 32 | RoW | CAELYX, Topotecan HCl | Xian-Janssen Pharmaceutical Ltd. | Epithelial Ovarian Cancer | 05/14 | 08/14 | | |
